Stock Events

Stock Events

Cassava Sciences 

$1.74
345
+$0.01+0.58% Wednesday 04:00

Statistics

Day High
1.74
Day Low
1.74
52W High
-
52W Low
-
Volume
899
Avg. Volume
-
Mkt Cap
84.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 12
$5.25
Dec 10
$2
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6MayExpected
Q3 2025
Q4 2025
Next
-0.3
-0.27
-0.25
-0.22
Expected EPS
-0.23
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-136.27MNet Income

Analyst Ratings

$8.00Average Price Target
The highest estimate is 8.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SAVA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Biogen is a leading competitor in the Alzheimer's treatment market, directly competing with Cassava's simufilam.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has developed donanemab, an Alzheimer's disease treatment, competing in the same space as Cassava Sciences.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a history of developing treatments for neurological disorders, including Alzheimer's, making it a competitor.
AC Immune SA
ACIU
Mkt Cap340.03M
AC Immune SA focuses on developing treatments for neurodegenerative diseases, including Alzheimer's, directly competing with Cassava.
Annovis Bio
ANVS
Mkt Cap48.93M
Annovis Bio operates in the Alzheimer's and Parkinson's disease space, making it a competitor to Cassava Sciences.
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Anavex Life Sciences Corp. is working on treatments for Alzheimer's disease, competing in the same market as Cassava.
Athira Pharma Inc
ATHA
Mkt Cap16.39M
Athira Pharma focuses on regenerative therapies for Alzheimer's, positioning it as a competitor to Cassava Sciences.

About

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Show more...
CEO
ISIN
US14817C1071

Listings

MX
MX
FLNA.MX
XNAS
US
SAVA
F
DE
PX91.F
BOATS
BOATS
SAVA.BOATS

0 Comments

Share your thoughts

FAQ

What is Cassava Sciences stock price today?▼
The current price of SAVA.BOATS is $1.74 USD — it has increased by +0.58% in the past 24 hours. Watch Cassava Sciences stock price performance more closely on the chart.
What is Cassava Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cassava Sciences stocks are traded under the ticker SAVA.BOATS.
What is Cassava Sciences market cap?▼
Today Cassava Sciences has the market capitalization of 84.06M
When is the next Cassava Sciences earnings date?▼
Cassava Sciences is going to release the next earnings report on May 06, 2026.
What were Cassava Sciences earnings last quarter?▼
SAVA.BOATS earnings for the last quarter are -0.26 USD per share, whereas the estimation was -0.3 USD resulting in a +13.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cassava Sciences revenue for the last year?▼
Cassava Sciences revenue for the last year amounts to 0 USD.
What is Cassava Sciences net income for the last year?▼
SAVA.BOATS net income for the last year is -136.27M USD.
Does Cassava Sciences pay dividends?▼
Yes, SAVA.BOATS dividends are paid en. The last dividend per share was 5.25 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Cassava Sciences complete a stock split?▼
Cassava Sciences has not had any recent stock splits.